AU Patent

AU2018229817B2 — Manufacture of a crystalline pharmaceutical product

Assigned to Orion Oyj · Expires 2021-09-30 · 5y expired

What this patent protects

The present invention relates to crystalline particles of N-((

USPTO Abstract

The present invention relates to crystalline particles of N-((

Drugs covered by this patent

Nubeqa (darolutamide) · Bayer

Patent Metadata

Patent number: AU2018229817B2
Jurisdiction: AU
Classification: —
Expires: 2021-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Orion Oyj
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.